Back to All Collaborations

Advancing Science to Prevent HIV & Empower Women & Girls

Active Since: 2004

Contributing to SDGs…

The collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson, and the International Partnership for Microbicides (IPM) supports the development and delivery of innovative tools to enable women and girls in developing countries to protect themselves against sexual transmission of HIV.

PARTNER ORGANISATIONS

  • Private foundation or development organization

    International Partnership for Microbicides

Objectives

  • Support the development and delivery of innovative tools to equip women and girls in developing countries with tools to protect themselves against sexual transmission of HIV.

What are the health needs and challenges?

HIV/AIDS remains among the greatest obstacles to women’s health and development. Although remarkable advances have been made in reducing new infections, progress has largely left women behind. In some parts of sub-Saharan Africa, young women and adolescent girls ages 15 to 24 are as much as eight times as likely to be infected as their male counterparts. Since stopping HIV’s spread among women requires a range of options to meet women’s individual needs, new tools including microbicides and multipurpose prevention technologies are being developed.

Partnership activities and how they address needs and challenges

The collaboration between Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the International Partnership for Microbicides (IPM) supports the development and delivery of innovative tools to enable women and girls in developing countries to protect themselves against sexual transmission of HIV.

This is done by granting IPM royalty-free license in order to develop and commercialize its HIV medicine in a number of developing countries and use its HIV medicine darunavir as a potential vaginal and rectal microbicide for HIV prevention in women.

This represents the first time a pharmaceutical company has licensed a protease inhibitor to be developed as a microbicide. The license will ultimately ensure that any new product will be provided at low cost in the settings where it is most urgently needed.

Quote
"Our goal is to make HIV history. Much more remains to be done in the fight against HIV and thats especially important in the worlds most vulnerable communities."
Alex Gorsky
Chairman and CEO of Johnson & Johnson

SDGs THE PARTNERSHIP CONTRIBUTES TO

SDG 3: Good Health and Wellbeing

  1. 3.3: Communicable Diseases & NTDs

SDG 5: Gender Equality

SDG 17: Partnerships for the Goals 

RESULTS & MILESTONES

As part of Johnson & Johnson’s multi-year partnership with the nonprofit International Partnership for Microbicides (IPM), IPM applied to the European Medicines Agency for approval of their monthly dapivirine vaginal ring that reduces the risk of HIV-1 infection in young women, offering a discreet prevention tool for women.